All In Biotech

Drug Trial Radar · NCT05860582

A Study of [14C]GB491 in Male Healthy Subjects

A Study of [14C]GB491 on Mass Balance and Biotransformation in Chinese Male Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Sep 14, 2022

Primary completion

Nov 14, 2022

Study completion Nov 14, 2022

Sponsor

Lead sponsor
Genor Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single-center study to evaluate the mass-balance and pharmacokinetics of GB491 in 4-8 healthy male subjects receiving a single oral 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491. This study will help understand how the drug appears in the blood, urine, and feces after it is administered. In addition, this study will also evaluate the safety of a single dose of \[14C\]GB491 when given to healthy subjects.

Conditions

  • Breast Cancer
  • Nonsmall Cell Lung Cancer

Interventions

  • [14C]GB491Drug

    A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total radioactivity in plasma PKTime frame: Up to 168 hours post dose
  2. Total radioactivity in urine and fecal samplesTime frame: Up to 360 hours post dose
  3. Metabolite G1T30 and other major matabolites (if applicable)Time frame: Up to 168 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Boren Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.